Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is now widely recognized that various lowmolecular weight HDAC inhibitors are broadly neuroprotective, preventing or delaying neuronal death and dysfunction in many rodent models of neurodegeneration. The beneficial effects result in part from modifications of histones and nonhistone proteins. This review describes evidence indicating that HDAC inhibitors have emerged as a promising new strategy in treating neurodegenerative disorders and summarizes treatment strategies from clinical trials currently underway.
INTRODUCTION
Neurodegenerative diseases are a heterogeneous group of disorders that have an increased incidence with the aging population. These disorders are characterized by progressive brain and spinal cord damage that gradually decimates functions of the central or peripheral nervous systems such as thinking skills, ability to recall and the capacity to do simple tasks. The most common neurodegenerative diseases include Alzheimer disease (AD), Parkinson disease (PD), Huntington disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and Friedrich ataxia (FRDA). Although research in experimental animals has greatly expanded our knowledge relating to the biochemical and molecular processes involved in the pathogenesis of neurological disorders, the corresponding therapeutic clinical approaches have failed to prevent progression of impairments.
Recently, epigenetic modulators have received considerable attention and have spurred justified hope as therapeutic strategies against development of neurodegenerative changes. Epigenetic modifications of chromatin have profound effects on cell-specific gene expression. One type of modification is the acetylation and deacetylation of lysine residues within the amino terminal tails of histone proteins. This coordinated process is carried out by 2 classes of nuclear enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), the major factors in epigenetic mechanisms regulating transcription. HATs catalyze the transfer of the acetyl group from acetylo-CoA to the epsilon-amino site of lysine, neutralizing the positive charge on histones. An increased level of histone acetylation is associated with the release of condensed chromatin and enhanced gene transcription activity. HDACs, on the other hand, promote chromatin condensation and gene silencing. Thus, a regulated shift in the balance between acetylation and deacetylation within the chromatin results in changes in gene expression patterns (1) . Although histones are the most intensively investigated substrates, various nonhistone proteins may be also modified by HATs and HDACs, including transcription factors, cytoskeletal proteins, signal transduction mediators, and molecular chaperons (2, 3) . Hence, disruption of acetylation homeostasis by a reduction or loss of HATs (deacetylation or hypoacetylation), and in consequence aberrant transcriptional activity, may have a serious impact on cellular functioning.
There are 2 main protein families with HDAC activity: The "zinc-dependent" classical HDAC family and the "nicotinamide-adenine-dinucleotide (NAD)-dependent" sirtuin (SIRTs) family, which are sometimes referred to as class III HDACs. Depending on sequence similarity, the zincdependent family members are categorized into 4 different classes (I, IIa, IIb, and IV), which differ in structure, enzymatic function, subcellular localization and expression patterns (Table 1) . To date, 18 deacetylases have been identified in mammals. Biological functions of individual HDACs have been difficult to define due to the lack of isoform-specific inhibitors. This obstacle is related to the high sequence homology within the catalytically active sites of HDACs. Moreover, constitutive knock-out (KO) of many of the individual HDACs are lethal, underscoring the vital role of these enzymes in normal development, but rendering the use of constitutive KO models unsuitable for study in the adult. Conditional KO and small interfering RNA strategies are now being employed to study the unique functional profiles of individual HDAC isoforms (4) . Almost a decade ago, studies documented for the first time the decreased level of histone acetylation in 2 different pathological contexts: Amyloid precursor protein (APP)-dependent signaling and in an ALS model (5) . Since then the linkage between histone hypoacetylation and neurodegeneration has been postulated in numerous cognitive and movement dysfunctions associated with degenerative conditions. Moreover, HDAC enzymes have been identified as attractive targets for therapy (6) . Indeed, employment of chemical HDAC inhibitors (HDACis) has been shown to have therapeutic efficacy in many rodent models of neurodegeneration, and several of these are currently in preclinical or phase I/II trials for the treatment of diseases ( Fig. 1) (5, (7) (8) (9) .
HDAC inhibitors are a heterogeneous group of agents that promote posttranslational acetylation of lysine residues within nuclear and cytoplasmic proteins, which may alter their activity and function. To date, numerous HDACis have been synthesized or isolated as natural products that have various target specificity, pharmacokinetic properties and activities in laboratory and clinical settings. Inhibitors of the classical HDAC family can be grouped into diverse classes based on their chemical structure. These include short chain fatty acids, hydroxamic acid derivatives, benzamides, cyclic peptides, and a few substrates not assignable to these categories. The most commonly used HDACis are presented in Table 2 .
Most HDACis are broad spectrum and affect multiple HDACs and thus are known as "pan-HDAC inhibitors". Unfortunately, isoform-specific inhibition of HDACs still remains a challenging task. In many cases these compounds exhibit a high degree of lipophilicity and are difficult to design due to the above noted high sequence homology within the catalytic domain of HDACs, rendering them more useful as tools for research (10) . Only a few newly characterized HDAC inhibitors are now available that preferentially inhibit specific HDAC classes, such as CHR-3996 (inhibits class I). In addition, selective inhibitors have been developed for HDAC6 (tubacin and tubastatin).
This review describes current data related to the effect of various HDACis in cellular and animal models of select neurodegenerative diseases and their potential employment in therapeutic management. Additionally, it summarizes promising treatment strategies from clinical trials that are currently underway.
ALZHEIMER DISEASE
Alzheimer disease (AD) is the most common neurodegenerative disorder in the elderly and is the fifth leading cause of death in individuals aged 65 or older. The disease accounts for $80% of all cases of dementia that arise from progression of cognitive impairment and memory loss associated with neuronal dysfunction and eventual neuronal death (11) . Moreover, AD also comprises noncognitive symptoms such as delusions, agitation and changes in mood and personality (12) . Pathologically, AD is characterized by extracellular amyloid plaques and intraneuronal neurofibrillary tangles (13, 14) . Amyloid senile plaques are aggregates of 40-42 bÀamyloid peptides released following the cleavage of amyloid precursor proteins that form neurotoxic oligomers (15, 16) . The other hallmark of pathology is intracellularly accumulated neurofibrillary tangles of abnormally phosphorylated tau proteins, which cause reduction of microtubule assembly and participate in the progressive neurodegeneration (17) . Amyloid constituents and neurofibrillary tangles are observed in 2 forms of the disease-familial and sporadic. While the familial form is caused by mutations in the presenilin 1 (PS1) and amyloid precursor protein (APP) genes or the genes that mediate its processing, the sporadic disease is most likely a result of a common action of genetic and environmental factors. Despite the significant progress in knowledge relating the pathology of this disorder, the treatment options remain limited and are focused only on managing symptoms as in other neurodegenerative disturbances. In the past, research focused mainly on amyloid deposition; however, the corresponding therapeutic clinical approach failed (18) .
Testing diverse approaches to ameliorate AD pathology is possible because of the many animal models that reflect specific aspects of this disorder. Most of the transgenic mouse models overexpress mutant human APP, presenilin 1 and/or microtubule-associated protein tau. The first transgenic model to be developed was the PDAPP mouse that overexpresses APP with a familial form of Alzheimer disease (FAD)-associated Indiana mutation (V171F) (19) . This model shows a pronounced increase of amyloid plaque deposition between 6 and 9 months with the expression of APP, which is $18-fold higher than endogenous levels. Another commonly used AD model is the Tg2576 mouse line, which overexpresses human APP with FAD-associated Swedish mutations (K670N, M671L) (20, 21) . The mutations are located at the b-secretase cleavage site (aa670/1); through APP processing by the amyloidogenic pathway, this leads to an increase in overall levels of bÀamyloid. In general, most mutant APP-overexpressing mice present increased amyloid plaque pathology, loss of neurons, impaired synaptic plasticity and cognitive deficits (22) . Since epigenetic modifications, including histone acetylation, have been increasingly recognized as key mediators in genome environment interactions in neurodegenerative diseases, studies to reverse aberrant epigenetic states have been actively explored in recent years. In line with this, accumulating evidence from in vitro and in vivo investigations has shown that histone modifications and dysfunctions are associated with the etiology of AD. The role of epigenetic abnormalities related to acetylation have been discussed in 2 interesting recent reviews (23, 24) . The overexpression of APP detected in cultured cortical neurons led to H3 and H4 histones hypoacetylation. Moreover, aged mice exposed to HDAC inhibitors, in addition to the enhancement of histone acetylation, showed improvement in memory deficits (25) (26) (27) . Hence, given the role of histone acetylation in memory function, and the finding that HDAC inhibitors facilitated learning and re-established access to long-term memory, introducing these agents as a therapeutic approach for AD has been considered. Indeed, the efficacy of HDACis has been demonstrated in mice models of AD showing accumulation of extracellular bÀamyloid protein and hyperphosphorylated tau protein. One of the first studies noted that prolonged exposure to sodium butyrate not only increased H3 and H4 acetylation levels, but also ameliorated cognitive deficiencies and re-established synaptic plasticity in a mouse model with overexpression of p25 protein (subunit of cyclin-dependent kinase 5), which is implicated in various neurodegenerative conditions (28) . Furthermore, elevated levels of this protein have been confirmed in human AD patients (29) . Thus, the expansion of p25 protein has been linked both to amyloid and tau pathology in the aged mice and to memory impairment (30, 31) . Importantly, the inhibitor appeared to be effective when it was applied at a stage of severe disorders and even after the onset of neuronal cell death (28, 32) . In this context, in Tg2576 AD mice daily injections of 4-phenylbutyrate improved spatial memory by normalizing tau hyperphosphorylation in the hippocampus although without affecting A-beta levels (33) . The agent also reversed the loss of histone H4 acetylation and promoted GluR1, PSD95 and MAP2 expression, suggesting repression of transcription dysfunction. Several groups of researchers tested other HDAC inhibitors (such as TSA, VPA, and SAHA) using a fear-conditioned AD mice model. Application of these compounds led to synapse remodeling and enhancement of contextual memory. The observed response was associated with H3/H4 acetylation of relevant gene promoters and as a result induced hippocampal LTP (28, (34) (35) (36) (37) (38) . Subsequent studies confirmed the beneficial effect of a novel class HDAC inhibitor, mercaptoacetamide-based compound W2, with improved physicochemical properties compared with commercially available HDACis (39, 40) . W2 reduced amyloid plaque load and decreased tau phosphorylation in APP/PSI-21 and 3xTG AD mice models (41, 42) . The action of W2 was strongly supported by results reported by Sung et al showing that in the presence of the inhibitor several genes facilitating bÀamyloid production have been repressed, whereas the number of enzymes involved in bÀamyloid degradation were upregulated (41) . Thus, the ability of this agent to reduce amyloid pathology illustrates its value in future clinical trials.
An important issue regarding AD and other neurodegenerative diseases is the identification of the appropriate drug target isoform of HDAC. Recent studies have surprisingly found that HDAC2 and HDAC6 are the most suitable drug targets to treat memory deficits associated with AD (26, 43) . A follow-up study performed by Guan et al demonstrated that overexpression of HDAC2 isoform decreases synaptic plasticity and shows deficits in memory formation (36) . The analysis of HDAC6 function indicated an increased protein level in the cortices and hippocampi of AD postmortem brain samples (44) . Reducing endogenous HDAC6 restores the learning and memory deficits in a severe AD model (APPPS1-21 mice) by rescuing axonal transport through a-tubulin acetylation. So, these results argue that inhibition of axonal transport can cause functional deficits in vivo (43) . However, the beneficial effects of depleting HDAC6 may not just stem from its action on microtubules per se, but also from its effect on tau, which once acetylated is protected from pathogenic hyperphosphorylation and aggregation (45) .
Other studies focused on the role of nicotinamide, the competitive inhibitor a class III HDACs (sirtuins). The treatment of 3xTg-AD mice with nicotinamide prevented memory impairments and decreased tau pathology without any effect on b-amyloid load or production (46) . Thus, in the light of these data the development of selective inhibitors is urgent. Clearly, it remains to be determined whether treatment with these newly synthetized agents will really modify the disease.
PARKINSON DISEASE
Parkinson disease (PD) is one of the most common neurodegenerative brain disorders, affecting $2% of the population over the age of 65 (47, 48) . The main features of this pathology are progressive motor dysfunctions, such as hypokinesia, resting tremors, difficulty in starting a movement, postural instability, muscle rigidity, bradykinesia, and mask face. Moreover, nonmotor symptoms such as olfactory deficits, constipation, sleep behavior disorders, cognitive impairment, mood disturbances, and dementia are also observed in PD patients (48, 49) . The neuropathological hallmarks required for a PD diagnosis are the presence of Lewy bodies and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), causing depletion of dopamine in striatal projections (50, 51) . Lewy bodies are proteins deposited in the neurons composed of pathologic misfolded a-synuclein, which play a key role in damage of dopaminergic neurons (52) . Although Lewy bodies can be found in neuronal cells in some neurodegenerative diseases such as AD, they are more prominently produced in SNpc of individuals with PD. The cause of PD is not yet recognized. Evidence from the literature shows that several environmental determinants (herbicides, pesticides, and industrial chemicals) are linked to the etiology of PD (53) . Meanwhile, growing data indicate that in some cases the genetic background contributes to the occurrence of the disease and thus numerous genes for monogenic types of PD have been recognized (54) (55) (56) .
To understand PD mechanisms, several animal models were developed. The first models of the disease were generated using neurotoxins, such as 6-hydroxydopamine (6-OHDA), MPPþ (1-methyl-4-phenylpyridinium), 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and rotenone. The administration of toxins to rodents induces typical signs and symptoms of the disorder, for example, motor impairments, death of dopaminergic neurons in the substantia nigra, reduced striatal dopamine levels, energy depletion and neuroinflammation (57, 58) . Because most of the neurotoxins do not develop a-synuclein intraneuronal inclusions resembling pathognomonic Lewy bodies, transgenic animals (Drosophila and mice) have been generated to obtain models that more closely recapitulate progression of human disease pathology (59) .
Although the exact molecular basis responsible for the nigrostriatal degeneration in PD is still not clearly understood, increasing evidence suggests the involvement of transcriptional dysregulation in the disease pathology. In agreement, gene expression modulated by histone acetylation has been found to be altered in animal models as well as in PD patients (60, 61) . Some reports have pointed to nuclear localization of a-synuclein in a variety of experimental systems including Drosophila (62), mice (63) , and cultured cells (64) and, importantly, in patients with multiple system atrophy clinically related to PD (65, 66) . According to this data, nuclear asynuclein binds to histones in vitro and in vivo, which results in a simultaneous reduction of histone acetylation. Hence, it has been speculated that this event is probably harmful for dopaminergic neurons (63, 67) .
Since the discovery that histone deacetylation may be involved in PD pathology, treatment with various HDAC inhibitors has emerged as a promising strategy for therapeutic intervention. A number of experiments were performed using drugs tailored to target HDAC activity in PD models (61) ; the studies primarily focused on the currently available group of pan-inhibitors.
One of the compounds that attracted a great deal of attention was a pan-inhibitor of HDAC classes I and II, valproate. The administration of this compound prevented the reduction of dopaminergic neurons in SNpc and protected dopaminergic neuronal terminals in the striatum in PD induced by neurotoxins (rotenone or MPTP) (68) (69) (70) (71) . The beneficial result was related to increased histone H3 acetylation-one of the mechanisms of valproate action. Correlating with neuroprotection and increased histone acetylation, the authors found a transcriptional induction of neurotrophic factors, such as GDNF and BDNF, not only in various neuron-glia cultures but also in vivo (72, 73) . In addition, the treatment revealed a significant activation of numerous molecular targets involved in neuroprotection, such as GSK-3, Akt/Erk pathways, Na þ and K þ voltage-dependent channels and oxidative/phosphorylation pathways (74) .
Finally, valproate signaling has emerged as an attractive compound that inhibits neuroinflammation, indicated by reduced activation of microglia followed by suppression of inflammatory marker release, both of which accompany neurodegeneration (73, 75) . Of note, the obtained results should be carefully interpreted, as the drug was administered prior to toxin treatment. Considering that at the time of PD symptom onset, a large majority of cells is already lost within the SNpc of patients, drug application should follow the exposure to toxin. Hence, it seems rather premature to speculate that valproate would be able to affect all of the pathological reactions associated with PD. Of interest, 2 clinical trials of valproate conducted years ago in PD patients did not result in any significant amelioration of symptoms (76, 77) . Nevertheless, the Committee on Research of the American Neuropsychiatric Association deemed valproate one of the most promising agents in PD cases.
Effective protection of dopaminergic neurons and improvement in motor dysfunction in several models of PD, among them in an a-synuclein transgenic fly model and 6-OHDA-treated rats, was also observed using short chain fatty acids such as sodium butyrate and phenylbutyrate (PBA) (67, 73, (78) (79) (80) . Importantly, the effectiveness of HDAC inhibition has been noticed even after the process of neurodegeneration has begun. The mode of action is most probably associated with increased histone acetylation, which was found with concomitant elevation of BDNF and GDNF, reduction of caspase-3 activity, attenuation of oxidative stress and neuroinflammatory markers.
The administration of PBA diminished the loss of dopamine and, in addition, its metabolite-3, 4-dihydroxyphenylacetic acid (DOPAC), as well as homovalinic acid in the striatum. A significant finding of this study was that PBA protected endangered by neurotoxins tyrosine hydroxylasepositive neurons (81, 82) . Moreover, it was reported that PBA reduced aggregation of a-synuclein and prevented deterioration of motor symptoms and cognitive decline in a transgenic animal model of a-synuclein accumulation (83) .
Increasing the attractiveness of the fatty acid derivatives PB and PBA as drugs for potential PD treatment are more recent findings that both inhibitors can upregulate DJ-1 protein in the brains of mice treated with MPTP toxin. Protein deglycase DJ-1, also known as PD protein 7, is encoded in humans by PARK7 gene. DJ-1 has different activities, including regulation of mitochondria, proteases, transcription and anti-oxidative stress response. Follow-up studies revealed its implication in the initiation and progression of PD. In line with this, increased expression of this protein rescued cultured rat mesencephalic dopaminergic cells from mutant a-synuclein toxicity. Taken together, the reported findings prompted the succession of further investigations showing that PBA inhibitor may be an important agent in the therapy of PD (84) .
Another exciting example of a HDAC inhibitor, which conferred protection in PD models, is the hydroxamic acid compound Trichostatin A (TSA). Like other HDAC inhibitors, TSA treatment enhanced histone acetylation in the brains. The beneficial effects of TSA have been observed in dopaminergic neurons, as well as in primary neuron-glia cocultures treated with MPTP. Furthermore, results from different sets of investigations showed that animals treated with TSA tended to have improved neurological scores compared with vehicle-treated animals. Like valproate and sodium butyrate, the neuroprotective effects of TSA were associated with an anti-inflammatory action expressed by apoptosis of microglia cells in culture (85) . Moreover, convincing evidence has shown that TSA upregulates the expression of neurotrophic factors, at least BDNF and GDNF, which could directly reduce neuronal cell death (73) . Pharmacokinetic studies carried out on animals indicate that TSA administered peripherally is quickly adsorbed and rapidly metabolized (86) . Another issue, not yet explored, is the precise concentration of the drug in the blood after an intraperitoneal injection. Hence, one cannot predict the relevance for human disease. Moreover, Wang et al found that an acute TSA dose exacerbates dopaminergic cell death caused either by MPPþ or the mitochondrial toxin rotenone (87) . Probably some differences in the treatment regime, including among others toxin concentration, could account for this discrepancy. Nevertheless, it complicates the application of the inhibitor.
Despite a significant body of data concerning the action of the above-described inhibitors in experimental PD models, there is no data demonstrating the effect of the hydroxamic derivative vorinostat (SAHA), already approved for advanced primary cutaneous T-cell lymphoma. To our knowledge, vorinostat has been used in only one study and has demonstrated protection of 2 different dopaminergic neuronal cell lines from apoptotic cell death induced by MPPþ (78) . The effect was undoubtedly associated with HDAC inhibition.
In contrast to pan-inhibitors, more selective agents have been recently developed: A cyclic tetrapeptide apicidin and romidepsin. Apicidin presents the ability to inhibit the action of distinct subclasses of HDACs (HDAC2, HDAC3 and HDAC8) with relatively high potency (88) , while romidepsin appears to be a highly potent inhibitor of HDAC2, which is thought to be a key player in mediating cognitive impairment in the degenerating brain (26) . The specific nature of these compounds may represent an attractive therapeutic avenue for investigation, even more so because HDAC2 and HDAC3 are 2 of the most highly expressed HDAC classes within the substantia nigra. The selectivity of both inhibitors should be considered as an advantage for further treatment of the cognitive impairments observed in so many PD patients. However, there are no detailed studies yet regarding their neuroprotective ability in the disease.
Increased hope for PD treatment probably might bring a novel HDAC1/2 isoform-specific drug K560 (2-amino-5(tiophen-2yl)benzamide), with action directed against the 2 deacetylases, HDAC1 and HDAC2 (89) . K560 demonstrated neuroprotective efficiency in a differentiated SH-SY5Y cell line, as well as in an in vivo PD model induced in mice by toxin treatment. It should be noted that both pre and posttreatment with K560 conferred dopaminergic neuroprotection in the mouse model of PD. A detailed analysis showed that K560 attenuated cell death in SH-SY5Y culture through the sustained expression of an anti-apoptotic protein, X-linked inhibitor of apoptosis (89) . In addition, treatment also resulted in inactivation of mitogen-activated protein cascade and reduced p53 phosphorylation. Although the entire spectrum of molecular events resulting from HDAC inhibitor treatment in vivo is incomplete, up-to-date findings may provide insight into their clinical usage.
It is worth noting that until now we do not know which of the 11 zinc-dependent HDAC family members are targets for neuroprotection in PD and in other neurodegenerative diseases. Equally unknown is whether efficacy can be obtained by targeting a particular HDAC. To date, only few research activities have focused on the role of individual HDACs in PD. In this context, particularly interesting is the paper published by Li et al describing the involvement of HDAC6 (90) .
HDAC6 plays a role in cellular function via enzymatic and nonenzymatic actions (91) . The catalytic domains of HDAC6 generate deacetylation of several nonhistone proteins, such as a-tubulin, cortactin, and HSP90 (92, 93) , whereas the nonenzymatic action of this deacetylase is related to the ubiquitin binding domain, which perceives the accumulation of ubiquitinated misfolded proteins (94, 95) . The results indicate that HDAC6 promotes cytoplasmic inclusion formation and facilitates autophagic degradation of these aggregates in the aggresome. Therefore this action protects dopaminergic cells against a-synuclein toxicity and might have an important role in the suppression of neurodegenerative disorders (90) . This suggestion was confirmed by the effect of the HDAC6 inhibitor tubacin. Tubacin treatment led to defects in aggresome formation accompanied by massive cell death in response to misfolded protein-induced stress (96) . However, it is not clear whether HDAC6 is protective against neurodegenerative stimuli besides protein aggregation. Importantly, pharmacological inhibition of HDAC6 by another inhibitor, tubastatin, diminished ROS production (97) . This suggests that HDAC6 participates in the regulation of oxidative stress in PD. In addition, given that alterations in microtubule-based axonal transport have been observed in a Drosophila model of PD (98), the beneficial effects are likely to occur also via inhibition of HDAC6, although this is yet to be tested.
An interesting finding was demonstrated by Outeiro et al in which blocking of SIRT2 (another tubulin deacetylase belonging to Class III HDACs) with a specific inhibitor, AGK2, led to increased a-tubulin acetylation and rescued dopaminergic neurons both in vitro and in a Drosophila PD model (99) . Similarly, SIRT2 knockdown reduced the neurotoxic effect of a-synuclein. These observations suggest that both zinc-dependent HDACs, as well as SIRT2, are potential targets for therapeutic intervention in PD.
Taken together, these results are in favor of a neuroprotective role of the broad group of HDACis in PD models. However, in contrast to the beneficial results described above, Choong et al (89) failed to observe the protective effect of TSA, SAHA, and VPA in in vitro SH-SY5Y cell culture with MPPþ application mode, consistent with reports indicating that VPA induces apoptosis in differentiating hippocampal neurons and TSA inhibits survival of dopaminergic neurons (86, 100) . On the other hand, treatments with these inhibitors have also been associated with expression of neurotrophic factors GDNF and BDNF from astrocytes and inhibition of proinflammatory cytokine release from microglia. Such neurotrophic factors mediate the HDAC inhibitor-induced neurotrophic effects of preserving dopaminergic neuronal function and protecting dopaminergic neurons from neurotoxicity. It is worth noting that these studies were performed on homogenous neuronal cultures without supporting astrocytes. The role of inhibitor clearly depends on cell types and tissue specificity. Therefore, more work is needed to fully decipher the mechanism of HDACis action.
In spite of the fact that more information is needed, a pharmacological intervention by HDAC inhibitors seems to be a promising strategy for therapeutic benefits and is worthy of further investigation for future treatment of the PD.
HUNTINGTON DISEASE
Huntington disease (HD) is an autosomal dominant genetic neurodegenerative disease characterized by progressive chorea, movement dysfunction, cognitive impairments and behavioral disturbances (101) . HD is caused by an abnormally high number (over 36) of CAG repeats in the 5 0 end of the coding region of the huntingtin gene. The CAG repeats result in a misfolded and toxic mutant protein Huntingtin containing a 5 0 polyglutamine repeat region, which has altered characteristics such as a gain of self-aggregation property (102). This aggregate formation, which is responsible for secondary complications such as apoptosis, excitotoxicity, mitochondrial dysfunction, and transcriptional dysregulation, is associated with HD and is ultimately responsible for the disturbed neuropathological features. HD has a broad impact on functional capabilities of a person affecting movement, thinking and psychological behaviors (103) . The disease is fatal $20 years after the onset of symptoms and there are no proven treatments that are able to delay the onset or slow the disease progression. In consequence, some brain areas degenerate with striatum being most severely affected (104, 105) . The hypothesis that the generation of a toxic fragment of a huntingtin is a critical event in HD pathogenesis has been supported by studies in transgenic mice (e.g. R6/2 or HdhQ150), which recapitulate many features of the human disease (8, 106, 107) . Transgenic HD mice carry a fragment of the 5 0 N-terminal human mutant HTT gene (e.g. R6/2, N171-82Q) or the entire human mutant HTT transgene (full-length models, such as the YAC128 or BACHD). The R6/2 mouse model with $150 CAG repeats is most commonly used for HD studies (108) . Another often applied transgenic model, N171-82Q, includes a N-terminal fragment of the HTT gene, with exons 1 and 2, expressing the first 171 amino acids with 82 glutamines (109). These HD models create an aggressive and rapidly progressing phenotype with striatal atrophy, modest degeneration of striatal medium-sized spiny neurons (MSNs) at the late stage of the disease, ventricular enlargement, and a failure to gain weight (108) (109) (110) (111) .
Although the exact cause of neuronal death remains undefined, early reports suggested transcriptional dysregulation initiated by a direct interaction of huntingtin with transcription factors and then perturbation of gene transcription pattern (112) (113) (114) (115) (116) . Further systematic studies of brains of HD transgenic mice (N171-82Q and R6/2) and HD human patients also demonstrated robustly reduced histone H3 and H4 acetylation (8, 117) . These findings indicate that HDACs might play an important role in the pathogenesis of HD. It has been speculated that rescuing the level of acetylated histones might be effective in reducing HD pathology. Indeed, pan-HDAC inhibitors (SAHA, sodium butyrate, or PBA) have been successfully introduced in cell culture systems with nuclear-targeted polyglutamine, in Drosophila and in transgenic R6/2 and N171-82Q mice models of HD (115, (118) (119) (120) . Treatment with these agents led to amelioration of the neurodegenerative phenotype, improvement in motor performance and extended animal survival (121) (122) (123) (124) (125) (126) . It is worth noting that low doses of PBA have shown the ability to correct transcriptional abnormalities in the blood of HD patients (127) and increase renal excretion of potentially neurotoxic indole metabolites, as seen in the recent phase II study with individuals with early symptomatic HD (128) . HDAC inhibitors act primarily by increasing histone acetylation in the brain and by this recover the balance between acetylation/deacetylation processes. In this context, identification of HDAC isoforms that play a prominent role in HD become an important issue.
To date, evidence has shown that 2 closely related HDACs, HDAC1 and HDAC3, participate in modulation of the transcription machinery and are responsible for gene expression abnormalities relevant in HD. It was further supported by findings that both isoforms translocate into the nucleus in the presence of mutant huntingtin (Htt) (129, 130) but, according to Bardai et al (131) , recruitment of HDAC3 facilitates the toxic effect. Likewise, such response was also observed in neurons exposed to apoptotic stimuli in the striatum of R6/2 HD transgenic mice. Therefore, it has been thought that targeting these isoforms may be neuroprotective. Recently developed benzamide-derived compounds such as HDACi 4b and related compounds (e.g. HDACi (106, 136) ), which tend to target HDAC1 and HDAC3, showed beneficial effects with potentially less toxicity compared with previously available agents. The detailed study of the effect of HDACi 4b treatment resulted in amelioration of the disease phenotype in several model systems: R6/2 transgenic mice, N171-82Q transgenic mice, StHdh Q111 striatal cells, and in Httex1pQ93 Drosophila (105, 107, 124, 129) . The effects of these HDACis were accompanied by elevation of histone acetylation and thereby with altered chromatin structure and promotion of gene transcription (107, 132) . HDACi 136 was the most efficacious at restoring gene expression abnormalities elicited by mutant Htt protein, correcting deficits in 8 of the 13 genes tested (129) . Administration of these benzamide-derived drugs improved disease-associated body weight loss, motor dysfunction, and cognitive decline (107, 124, 129) . It should be also pointed out that HDACi 4b prevents or reduces Htt aggregate formation by promoting degradation and/or clearance of misfolded Htt fragments.
There are conflicting results regarding the key role of a particular HDAC in HD pathology. According to Jeong et al, HDAC1 played a prominent role in reducing huntingtin protein (133) . Further evidence implicating HDAC1 as a single target comes from work showing that knock-down of HDAC1 in Htt590-97Q-transfected Neuro2a cells leads to a specific increase in acetylation of lysine 444 of the huntingtin protein, promoting its degradation by the autophagy pathway. The key role of HDAC1 in comparison to HDAC3 was additionally supported by Jia et al who did not observe a decrease in the level of huntingtin aggregates in the striatum of N171-82 transgenic mouse in response to HDAC3 inhibition (105) . Conversely, a study using HeLa cell line expressing huntigtin exon 1 has implicated HDAC3 isoform in controlling huntingtin levels (134) . It is likely that the aggregation pathways in nonneuronal cultured cells differ from those in the transgenic mouse brain, as the investigated HDAC isoforms may act on different targets and induce opposite effects. For the sufficient clearance of misfolded Htt fragments, further studies are needed to determine the HDAC isoform responsible for huntingtin aggregation.
In the light of gathering data showing the beneficial effect of HDAC1 and HDAC3 inhibition, the finding that genetic knock-down of HDAC3 in R6/2 mice does not influence physiological or behavioral phenotypes is rather surprising. It may be due to only a 20% reduction of HDAC3 overall protein level in the heterozygous double mutant animals, which probably occurred to be insufficient to induce significant changes in HD phenotypes. The efficacy might be seen in a more than a 50% knock-down of the HDAC3 gene (135) . Of note, genetic studies are not the same as pharmacological studies, where the dosage and length of drug treatment can be altered. Nevertheless, the relative genetic lack of amelioration does raise the hope that HDACis might have a beneficial effect by increasing acetylation of nonhistone substrates such as mitogen activated protein (124, 136) . For instance, inactivation of a SAHA inhibitor target, HDAC4, ameliorates degeneration in R6/2 mice by acting on the mutant Htt aggregation process (137) . Moreover, when striatal culture cells were treated with an inhibitor of HDAC6, tubacin, a-tubulin acetylation was increased and some features of HD pathology were reversed due to compensation of the BDNF transport carrying polyglutamine expansion (138) . On the other hand, it was found that expression of HDAC6 rescues in general polyglutamine-induced neurodegeneration associated with proteasome impairment by mediating the autophagic degradation pathway (139) . Considering the dual roles of HDAC6 in neurodegeneration and neuroprotection, the application of this subtype-specific inhibition should be preceded by further detailed analysis, as no specific HDAC6 activation or agonists have been studied in animal and clinical trials for HD. It is entirely possible that more nonhistone proteins are affected by the use of HDACis, and studies are required to determine the precise contribution of both histone and nonhistone protein hypoacetylation in HD (140) . In addition, although HDAC3 and 1 targeting occurred to be beneficial for HD therapeutics, this does not preclude involvement of other HDAC enzymes in the pathology or therapeutic application.
Nevertheless, independent of the mode of HDACi action in HD models, the reported histone and transcription mechanisms might have important implications for forthcoming therapy in individuals affected by this disease. Phase II studies provide indications for safety and tolerability of several agents, including PBA (127, 141) . The first report of HDACi usage in HD patients involved oral administration of sodium PBA in a phase I study. It was found that the 15 g/day dose was safe and was confirmed in a still unpublished phase II PHEND-HD study. It is worth noting that an alternative approach for HDAC inhibition, which bypasses the side effects of pharmacological overdose, is to promote the induction of endogenous HDACi b-hydroxybutyrate by inducing ketogenesis through high fat/low carbohydrate diets in HD patients (142) . In addition to Class I and II HDACs, the NAD þ -dependent Class III HDACs, sirtuins, are also potential targets in HD. A neuroprotective effect was observed by genetic and pharmacological reduction of HDAC SIRT1 in HD models or patients using the inhibitor selisistat (143) (144) (145) . Conversely, another study demonstrated a beneficial effect of Sirtuin 1 activation in different HD animal and cell models due to reduced mHtt-induced hyperacetylation of stress-related proteins (146, 147) . Therefore, the effects of specific agents may require further investigation to optimally integrate HDAC inhibitors into clinical testing.
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease mainly affecting upper and lower motor neurons. The damage of motor neurons leads to a progressive muscle wasting, paralysis, and death within 2-5 years of diagnosis. Symptoms broadly encompass loss of control of voluntary muscle movements and muscular atrophy (148) . ALS can be divided into 2 categories: Sporadic and familial ALS. The most common form is sporadic ALS (90%-95%), with no clear inherited components. Familial ALS is seen only in $5%-10% of the cases, where a genetic dominant inheritance can be associated (149, 150) . Although mechanisms precipitating motor neuronal death have not been precisely defined, studies in animal models of ALS and human patients revealed a plethora of alterations such as increased glutamate-mediated excitotoxicity, increased apoptosis, defective axonal transport, oxidative stress, mitochondrial dysfunction, and sustained upregulated immune responses, involved in pathogenesis of ALS (151) (152) (153) . However, the primary event leading to pathogenicity is still a matter of debate. Recent evidence suggests that transcriptional dysregulation and alterations in the transcriptome may play a role in the pathogenesis of bothfamilial and sporadic form of ALS (154) (155) (156) (157) .
Missense mutations in the enzyme copper-zinc superoxide dismutase type 1 (SOD1) gene cause $25% of familial ALS cases (158) and clinical and pathological features are indistinguishable from those in sporadic ALS. This has prompted the view that all forms of the disease may be better understood by studying pathogenesis and therapy in rodent models of ALS. Different transgenic mice overexpressing SOD1 mutation, where a glycine is substituted by an alanine at amino acid position 93 or by arginine at amino acid position 86 (G86R and G93A), have been developed as ALS models. These transgenic mice show progressive hind limb tremor and weakness, locomotor deficits and paralysis followed by premature death which reflect many of core clinical features strikingly similar to those in human disease (159) (160) (161) .
Rouaux et al were the first to report a decrease in histone H3 acetylation level, specifically in the motoneuron nuclei in a rodent model of ALS (G86R mutant SOD-1 mice) (5). In agreement with this, human postmortem study has provided clear evidence for deregulation of histone acetylation in ALS. Thus, it was hypothesized that maintaining proper acetylation levels in ALS cases by using HDAC inhibitors would be beneficial, as in some aspects of other neurodegenerative diseases (162) (163) (164) . VPA, one of the first tested agents administered to transgenic ALS SOD1 mice did not improve survival or motor performance but slightly delayed the onset of motor decline, without being able to prevent disruption of neuromuscular junction (165, 166) . Unexpectedly, the beneficial effect was noticed by chronic pre-onset VPA treatment, which significantly increased survival of G93A mice (167) . VPA has already been tested in ALS patients in 1 clinical trial. The administered doses were the same as those commonly used to treat epilepsy, however, this strategy did not show beneficial effects on disease progression or survival prolongation (165) .
PBA, another pan-HDAC inhibitor, resulted in significant improvement in clinical and neuropathological phenotypes of the SOD1 (G93A) mice. PBA restored histone acetylation levels, increased motoneuron survival, life extent, and motor performances, as compared with vehicle treated animals, and, importantly, was effective even when administered at disease onset (168, 169) . Some experimental approaches in preclinical studies include a combination of PBA inhibitor with riluzole, the only drug approved for the treatment of ALS. It was found that such a strategy potentiated the beneficial effect of PBA on survival and motor performance, although the authors did not address the possible mechanism (170) . Furthermore, sodium PBA in combination with a synthetic anti-oxidant agent (AEOL 10150) has also been tested. The results showed a more extended survival as compared with either treatment alone (168) . Additionally, an enhanced neuroprotection by a combinatorial approach using VPA and a mood stabilizer (lithium) in a mouse ALS model (SOD1-G93A) was reported (171) . The combined strategy targeting different pathogenic mechanisms may prove to be an optimal approach for preventing motor neuronal death.
It is worth noting that PBA has already been tested in a phase II clinical trial. In recent studies, 26 participants completed the 20-week treatment phase and the administered compound was well tolerated and safe. PBA administration significantly increased acetylation in blood buffy-coat specimens. The lowest dose (9 g/day) was therapeutically efficient in improving histone acetylation levels; however, the therapeutic efficacy of such treatment was not analyzed (172) . In this context it is worth noting that hypoacetylation in humans with ALS in blood buffy-coat samples parallels the previous finding observed in G93A transgenic mouse model (169) .
Finally, in vivo treatment with TSA showed an increase in normalized histone acetylation, neuroprotection, and extended survival with partially restored normal phenotypes in microglia and motor neurons in a SOD1 G93A mouse model. TSA also protected against motor neuronal death, axonal degeneration, muscle atrophy, and neuromuscular junction denervation (173) . It is worth noting that Trichostatin, in contrast to VPA or butyrate, inhibits the HDAC6 isoform. This suggests that HDAC6 may play a role in ALS pathology. The absence of HDAC6 in ALS model (SOD1-G93A mouse) induces an increase in the levels of tubulin acetylation, which is probably associated with a prolongation of survival, without apparently affecting other neurological functions (174) . Remarkably, the specific inhibitor tubacin mainly affected deacetylation of a-tubulin, whereas the overall acetylation status of the histones was not altered (175) . On the other hand, the mutated SOD1 in the same model promotes the formation of SOD1-tubulin-HDAC6 complexes, thus increasing a-tubulin acetylation (176) . So far, the role of HDAC6 beyond epigenetic mechanisms remains unclear.
Although encouraging, the mechanisms of the neuroprotective effects of HDAC inhibition are not well understood and therefore, the translation to the clinic is limited. The reported beneficial effects of the investigated inhibitors were associated with amelioration of histone hypoacetylation in ALS mice. Moreover, in some experiments authors reported data referring to the probable mechanisms of action of the specific analyzed compounds. Thus, sodium valproate exerts the neuroprotective effect through CREB-binding protein (177) . The detailed study of PBA indicated expression of nuclear factor kappa B and blocked programmed cell death pathway (169) . It is postulated that the effects of TSA were linked to reduced gliosis and upregulation of the glutamate transporter (GLT-1) in the spinal cord (173) . However, the functional consequences in terms of histone acetylation changes and resulting gene expression changes remain unclear. Many other nonepigenetic related cellular processes dysregulated in the context of ALS pathophysiology might be targets for HDACis (e.g. microtubule dynamics and intracellular transport).
SPINAL MUSCULAR ATROPHY
Spinal muscular atrophy (SMA) is a childhood onset degenerative disease resulting from the selective loss of a-motor neurons in the spinal cord and leading to atrophy of limb and trunk muscles (178) . SMA is one of the leading genetic causes of infant death in the world. There is currently no method of treatment or preventing the disease. SMA results from ubiquitous survival motor neuron (SMN) protein deficiency due to homozygous deletions or mutations of the gene SMN1, which lead to muscle weakness and in severe cases respiratory distress, and retention of SMN2 (179). The severity of SMA depends on the copy number of SMN2 gene and the consequent levels of the SMN protein (180) (181) (182) (183) (184) (185) (186) .
Understanding the contribution of gene dysregulation provided the rationale for the use of epigenetic modulators such as HDAC inhibitors for SMA treatment. Inhibitors of HDAC activity have been identified as inducers of SMN2 transcription (187) . By increasing histone acetylation these HDAC inhibitors increase SMN2 promoter activity, which results in elevated SMN protein levels (84, (188) (189) (190) (191) (192) .
Animal models of SMA have been developed in zebrafish, Drosophilia, and mouse. Among them, the mouse models have been most widely accepted as viable models for SMA because they reflect the broad range of disease severity seen in human patients (193, 194) . To generate transgenic mice that mimic the mechanism of disease as well as display a SMA phenotype, human SMN2 has been incorporated into Smn null animals.
One class of drugs tested in mice containing 2 or 4 copies of the SMN2 gene included HDACis: Sodium butyrate (195) , VPA (196) , TSA (197) (198) (199) , and suberoylanilide hydroxamic acid-LBH 589 (200) . The compounds were administered to pregnant females at the embryonic stage (E15), and to animals at postnatal day 5, at 3 months and at 6-12 months. As a result, an increased SMN transcription, splicing and protein level, improved survival, motor function and muscle pathology was observed (193) . Oral delivery of butyric acid-based compounds, such as 4PBA and BA prodrugs, BA3G and VX563, delayed the disease end stage efficiently improving the life-span by $250% (201) . The beneficial effect of HDACis in SMA mouse models probably resulted from activation of neuroprotective pathways that are yet to be characterized.
Of note, 4PBA has already moved into human trials with SMA patients. The treatment with a dose of 500 mg/kg/ day for 7 days in a pilot study showed improvement in motor function as compared with their baseline measurement (202) . However, in a randomized, double-blind, placebo-controlled study, 4PBA did not improve the disease severity of type II SMA patients (203) . Thus, observing drug effects is challenged by interanimal and interindividual variability in responsiveness.
FRIEDREICH ATAXIA
Friedrich ataxia (FRDA) is an inherited recessive disorder characterized by progressive neurological disability. Atrophy of sensory and cerebellar pathways causes ataxia, dysarthria, fixation instability, deep sensory and loss of tendon reflexes. With progression of the disease, patients lose the ability to walk. In some cases, disease symptoms include vision and hearing loss, along with nonneurological manifestations of cardiomyopathy and diabetes (204) . FRDA is caused by partial deficiency of frataxin, an essential mitochondrial protein. Frataxin participates in the mitochondrial biogenesis of Fe-S (iron-sulfur clusters) and its deficiency results in multiple enzyme deficits, mitochondrial dysfunction and oxidative damage (205) (206) (207) . Mitochondrial iron accumulation severely impacts mitochondria-rich cardiomyocytes and some neurons (208, 209) and leads to sensory neuron degeneration in the dorsal root ganglia as well as cerebellar and spinocerebellar tract degeneration (210, 211) . Lifespan is markedly reduced with complications of cardiomyopathy being the major cause of death (212, 213) . Moreover, complete absence of frataxin gene is deadly in higher organisms, as observed in systemic knock-out models of Drosophila and mouse (214, 215) .
All FRDA patients carry a GAA-TTC triplet expansion in the first intron of the frataxin (FXN) gene coding for the mitochondrial protein product. The GAA triplet inhibits frataxin expression through heterochromatin-mediated suppression of FXN gene expression. The gene silencing coding frataxin protein is accompanied by H3 and H4 hypoacetylation and by increased trimethylation of Histone H3 at lysine 9 (H3K9) around the trinucleotide. Interestingly, histone modifications that are characteristic of silenced gene downstream of the GAA expansion were found in postmortem brain tissues from individuals with diagnosed FRDA (7, 216) . These findings suggest that restoring FXN gene expression may substantially slow the course of disease. Because deacetylated histones are generally associated with silent heterochromatin, it has been thought that HDAC inhibitors have the potential to revert heterochromatin to open conformation that allows gene expression (217) .
The development and use of animal and cellular models of FRDA is an essential requirement for the understanding of FRDA disease mechanisms and investigation of potential FRDA therapeutic strategies. To study the consequences of frataxin depletion transgenic mouse models with selective FXN deletions were generated (e.g. MCK, NSE, PRP, KIKO/ KIKI, and YG8R/YG22R). These FRDA models reproduce many characteristic features of the disease, including progressive spinocerebellar and sensory ataxia, hypertrophic cardiomyopathy, and some dimensions of diabetes (218) .
A substantial increase in frataxin in lymphoblastoid cells and in primary lymphocytes from FRDA patients was only obtained when using a specific class of HDACi analogues of the compound BML-210 (N -phenylheptanediamide) (7). FXN reactivation was coupled with increased acetylation of histone H3 and H4 in the chromatin region near the GAA repeats in human FRDA cells as well as in a FRDA mouse model that carriers expanded GAA repeats (7, 219, 220) . A novel KIKI mouse model (crossed with frataxin knock-out mice to obtain heterozygous mice) also presented a similar response to HDACi 106 treatment expressed by histone modification and restoration of frataxin levels in the CNS and heart, tissues that are relevant targets. In another study, HDAC inhibitors (pimelic o-aminobenzamide) improved the FRDA phenotype in a house mouse (Mus musculus) model (221) . Because no effect on frataxin level was observed in similarly treated WT mice, it can be inferred that agent 106 interferes with transcriptional repression mechanisms triggered by GAA expansion. However, according to reported data, KIKI mice do not show overt pathology or abnormal behavior, but present alterations in the overall gene expression profiles in relevant tissues and thus constitute a biologically fitting phenotype. These data highlight the potential of novel therapies aimed at increasing frataxin levels via epigenetic modulation. It is worth adding that HDAC inhibitor RG2833 has been already entered in a clinical trial for FRDA (7, 219, 222) . Because the inhibitors tend to target HDAC3, and this deacetylase is thought to play an important role in FRDA, there has recently been interest in developing more potent and specific inhibitors (220, 223) . A phase I clinical trial for such a 
Conclusions
The evidence reviewed here highlights the beneficial effects of several HDAC inhibitors in experimental models of different neurodegenerative diseases. The efficacy of these agents in ameliorating disease-associated symptoms (e.g. memory deficits, cognitive decline, motor dysfunction, and inflammation) provides a promising avenue for treatment in the clinical manifestation of degeneration. However, despite the scientific importance of animal models in understanding the pathogenic pathways leading to specific brain diseases, several key challenges must be overcome to translate the data to the clinic and exploit the neurotherapeutic potential of HDACis. One of the most urgent issues is the effective identification of isoform-specific HDAC inhibitors. Selective agents may prove more beneficial in targeting neurological disease symptoms and minimizing harmful side effects caused by global inhibition of HDAC proteins, which may cause a loss in the signal-nonspecific responses.
Another important aspect that can enable a more direct translation of rodent data to humans is related to the significant lack of information about the ability of HDACis to cross the blood-brain barrier and be effectively delivered to the CNS. It should be also pointed out that HDAC inhibitors are often administered systematically (e.g. intraperitoneally or orally). Such treatments face the risk of undesired side effects, not only in the target tissue but also in the whole body. Cytotoxic profile of HDACis requires more critical evaluation.
In summary, this review could serve as a guide for designing novel HDAC inhibitors with improved selectivity, specificity, efficient penetration of blood-brain barrier, sufficient metabolic stability in the target tissue, and with the least possible side effects, thereby guiding their therapeutic application in neurodegenerative disorders.
